Doubt that a merger would be the agenda but rather a collaborative ecosystem of synergistic platforms that contributes to the establishement of personalised medicine here in Aust and elsewhere. I see that the bases are being covered by all the companies in the Hopper stable. We just need for our CEO (and MD) to unveil where PTX now stands within the business model of ours at this juncture!
Here's yet another promising trial in the CAR-T space. A fast track designation for an autologous CAR T cell treatment for patients with renal cell carcinoma....
https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-ivs-3001-for-rccAnd, more and more pre-clinical evidence on what we already know:-
https://www.news-medical.net/news/20230803/CAR-T-immune-therapies-could-be-effective-against-solid-tumors.aspxIts well and good having OmniCAR and CellPryme on the sidelines, and two targeted therapies ongoing in the clinic, after having raised capital last year in two placements and this year by way of the option conversions, but being in the dark as to where we are now actually situated (on the wave). Is it too much to expect to be informed with tangible evidence of progress or, at the very least, guidance on timelines for our diversified pipeline that's supposedly meant to keep our investment on an even keel?
